Market Cap 172.28M
Revenue (ttm) 9.99M
Net Income (ttm) -149.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,492.59%
Debt to Equity Ratio 0.00
Volume 345,674
Avg Vol 1,678,832
Day's Range N/A - N/A
Shares Out 93.12M
Stochastic %K 49%
Beta 2.55
Analysts Strong Sell
Price Target $9.29

Company Profile

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 982 6030
Address:
2929 7th Street, Suite 105, Berkeley, United States
StealthSigma
StealthSigma Aug. 23 at 10:12 AM
$CRBU Caribou Biosciences Inc is a clinical stage cell therapy company with CRISPR platform
0 · Reply
3DBuilds
3DBuilds Aug. 23 at 2:36 AM
$CRBU FDA National Priority Voucher program 🤔 interesting CRISPR is definitely looking to be in this 👌 kk
0 · Reply
NicaInvest85
NicaInvest85 Aug. 21 at 11:15 PM
$CRBU they can’t be misleading: “Our clinical programs, CB-010 for large B cell lymphoma and CB-011 for multiple myeloma, continue to generate encouraging Phase 1 results, reinforcing our conviction in the potential of these therapies. We remain on track to report robust datasets from both programs this year, which we expect to provide meaningful insights into the potential of our approach and the future of allogeneic CAR-T cell therapies.”
4 · Reply
NicaInvest85
NicaInvest85 Aug. 21 at 11:13 PM
$CRBU I liked this from FSR: “Caribou is advancing allogeneic CAR-T cell programs to deliver off-the-shelf therapies designed for rapid treatment and broad patient access,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “Our clinical programs, CB-010 for large B cell lymphoma and CB-011 for multiple myeloma, continue to generate encouraging Phase 1 results, reinforcing our conviction in the potential of these therapies. We remain on track to report robust datasets from both programs this year, which we expect to provide meaningful insights into the potential of our approach and the future of allogeneic CAR-T cell therapies.”
0 · Reply
DimebagDarrell_
DimebagDarrell_ Aug. 21 at 10:03 PM
$CRBU C’mon, baby.
0 · Reply
Ewak21
Ewak21 Aug. 20 at 2:06 PM
0 · Reply
RocroBio
RocroBio Aug. 20 at 5:11 AM
0 · Reply
Mogeyman
Mogeyman Aug. 20 at 1:03 AM
0 · Reply
NicaInvest85
NicaInvest85 Aug. 19 at 3:43 PM
$CRBU still bullish on $CRBU as data needs to be released on their two potential drugs - it can be also delayed. Alec Stranahan, PhD, on Molecular Biology and Genetics, a Senior Analyst for BofA has a strong buy and a price target of $9. The analyst consensus is from $9-$32, all depends on FDA approval to phase 2 trials.
1 · Reply
3DBuilds
3DBuilds Aug. 18 at 9:48 AM
$CRBU new initiatives phase 1 CB-010 Gallop trail for lupus 👍 🤪
4 · Reply
Latest News on CRBU
StealthSigma
StealthSigma Aug. 23 at 10:12 AM
$CRBU Caribou Biosciences Inc is a clinical stage cell therapy company with CRISPR platform
0 · Reply
3DBuilds
3DBuilds Aug. 23 at 2:36 AM
$CRBU FDA National Priority Voucher program 🤔 interesting CRISPR is definitely looking to be in this 👌 kk
0 · Reply
NicaInvest85
NicaInvest85 Aug. 21 at 11:15 PM
$CRBU they can’t be misleading: “Our clinical programs, CB-010 for large B cell lymphoma and CB-011 for multiple myeloma, continue to generate encouraging Phase 1 results, reinforcing our conviction in the potential of these therapies. We remain on track to report robust datasets from both programs this year, which we expect to provide meaningful insights into the potential of our approach and the future of allogeneic CAR-T cell therapies.”
4 · Reply
NicaInvest85
NicaInvest85 Aug. 21 at 11:13 PM
$CRBU I liked this from FSR: “Caribou is advancing allogeneic CAR-T cell programs to deliver off-the-shelf therapies designed for rapid treatment and broad patient access,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “Our clinical programs, CB-010 for large B cell lymphoma and CB-011 for multiple myeloma, continue to generate encouraging Phase 1 results, reinforcing our conviction in the potential of these therapies. We remain on track to report robust datasets from both programs this year, which we expect to provide meaningful insights into the potential of our approach and the future of allogeneic CAR-T cell therapies.”
0 · Reply
DimebagDarrell_
DimebagDarrell_ Aug. 21 at 10:03 PM
$CRBU C’mon, baby.
0 · Reply
Ewak21
Ewak21 Aug. 20 at 2:06 PM
0 · Reply
RocroBio
RocroBio Aug. 20 at 5:11 AM
0 · Reply
Mogeyman
Mogeyman Aug. 20 at 1:03 AM
0 · Reply
NicaInvest85
NicaInvest85 Aug. 19 at 3:43 PM
$CRBU still bullish on $CRBU as data needs to be released on their two potential drugs - it can be also delayed. Alec Stranahan, PhD, on Molecular Biology and Genetics, a Senior Analyst for BofA has a strong buy and a price target of $9. The analyst consensus is from $9-$32, all depends on FDA approval to phase 2 trials.
1 · Reply
3DBuilds
3DBuilds Aug. 18 at 9:48 AM
$CRBU new initiatives phase 1 CB-010 Gallop trail for lupus 👍 🤪
4 · Reply
Mindegap
Mindegap Aug. 18 at 4:46 AM
$CRBU I see NO new/reactivated trial on their website. ZERO. Spreading false rumors makes you sound desperate.
1 · Reply
Jidane
Jidane Aug. 18 at 4:33 AM
$CRBU Usually, Biotech’s 2nd half means November or December. I don’t know why they just say 4Q.
0 · Reply
3DBuilds
3DBuilds Aug. 16 at 10:38 AM
0 · Reply
3DBuilds
3DBuilds Aug. 16 at 12:04 AM
0 · Reply
Peterson28
Peterson28 Aug. 15 at 11:42 PM
$CRBU Bad sign of reactivating a dropped trial. Management is looking for a plan B.
3 · Reply
3DBuilds
3DBuilds Aug. 15 at 8:40 PM
$CRBU over the weekend research more of it but i think Caribou added NEW trials for lupus to their pipeline for cures 👍 👌 yall know one of the ladys that got the Noble Prize for CRISPR found this company right 🤪 and it has an exclusive licenses to use the Tech 👍 💰 $$$
5 · Reply
3DBuilds
3DBuilds Aug. 15 at 4:15 PM
$CRBU added treatment to pipeline 👍 👌
2 · Reply
RocroBio
RocroBio Aug. 15 at 2:57 PM
0 · Reply
Ewak21
Ewak21 Aug. 15 at 2:35 PM
0 · Reply
boolfool
boolfool Aug. 15 at 12:24 PM
$CRBU $XLV $UNH CRBU should be getting more attention. Don’t sleep on it!
0 · Reply
boolfool
boolfool Aug. 14 at 9:47 PM
$CRBU Updated to $8 today FYI
0 · Reply
3DBuilds
3DBuilds Aug. 14 at 10:18 AM
0 · Reply